Importance of candida species other than c. Albicans as pathogens in oncology patients

Clinical Infectious Diseases

Volumn 20, Issue 1, 1995, Pages 115-125

  Wingard, John R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MARROW TRANSPLANTATION; CANCER PATIENT; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; DISEASE ASSOCIATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; REVIEW;

CANDIDA; CANDIDIASIS; HUMAN; NEOPLASMS; OPPORTUNISTIC INFECTIONS; RISK FACTORS; SPECIES SPECIFICITY;

EID: 0028891715     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/clinids/20.1.115     Document Type: Article

References (116)

1. Craig JM, Farber S. The development of disseminated visceral mycosis during therapy for acute leukemia [abstract]. Am J Pathol 1953:29:601.
2. Zimmerman LE. Fatal fungus infections com plicating other diseases. Am J Clin Pathol 1955;25:46-65.
3. Keye JD, Magee WE. Fungal diseases in general hospital: study of 88 patients. Am J Clin Pathol 1956;26:1235-53.
4. Gruhn JG, Sanson J. Mycotic infections in leukemic patients at autopsy. Cancer 1963;16:61-73.
5. Louria DB, Stiff DP, Bennett B. Disseminated moniliasis in the adult. Medicine (Baltimore) 1962;41:307-37.
6. Edwards JE Jr. Montgomerie JZ, Ishida K, Morrison JO, Guze LB. Experimental hematogenous endophthalmitis due to Candida: species variation in ocular pathogenicity. J Infect Dis 1977;135:294-7.
7. Hasenclever HF, Mitchell WO. Pathogenicity of C. albicans and C. iropicalis. Sabouraudia 1961; 1:16-21.
8. Hurley R, Winner HI. The pathogenicity of Candida iropicalis. J Pathol Bacteriol 1962;84:33-8.
9. Louria DB, Buse M, Brayton RG, Finkel G. The pathogenesis of Candida iropicalis infections in mice. Sabouraudia 1966-1967;5:14-25.
10. Winter WD, Foley GE. Candida infections in children with neoplastic disease: influence of therapy with antibiotics and steroid hormones. Pediatrics 1956;18:595-603.
11. Bodey GP. Fungal infections complicating acute leukemia. J Chronic Dis 1966;19:667-87.
12. Hart PD, Russell E, Remington JS. The compromised host and infection. II. Deep fungal infection. J Infect Dis 1969; 120:169-91.
13. Young RC, Bennett JE, Geelhoed GW, Levine AS. Fungemia with compromised host resistance: a study of 70 cases. Ann Intern Med 1974;80:605-12.
14. Hughes WT. Systemic candidiasis: a study of 109 fatal cases. Pediatr Infect Dis 1982;1:11-8.
15. Myerowitz RL, Pazin GJ, Allen CM. Disseminated candidiasis. Changes in incidence, underlying diseases, and pathology. Am J Clin Pathol 1977;68:29-38.
16. Meunier-Carpentier F, Kiehn TE, Armstrong D. Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality. Am J Med 1981;71:363-70.
17. Walsh TJ, Lee J, Lecciones J, et al. Empiric therapy with amphotericin B in febrile granulocytopenic patients. Rev Infect Dis 1991;13:496-503.
18. Maksymiuk AW, Thongprasert S, Hopfer R, Luna M, Fainstein V, Bodey GP. Systemic candidiasis in cancer patients. Am J Med 1984;77(suppl 4D):20-7.
19. Wingard JR, Merz WG, Saral R. Candida Iropicalis: a major pathogen in immunocompromised patients. Ann Intern Med 1979;91:539-43.
20. Kiehn TE, Edwards FF, Armstrong D. The prevalence of yeasts in clinical specimens from cancer patients. Am J Clin Pathol 1980:73:518-21.
21. Horn R, Wong B, Kiehn TE, Armstrong D. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis 1985:7:646-55.
22. Lowder JN, Lazarus HM, Herzig RH. Bacteremias and fungemias in oncologic patients with central venous catheters: changing spectrum of infection. Arch Intern Med 1982;142:1456-9.
23. Robinson GV, Tegtmeier BR, Zaia JA. Brief report: nosocomial infection rates in a cancer treatment center. Infect Control 1984;5:289-94.
24. Wingard JR, Vaughan WP. Braine HG, Merz WG, Saral R. Prevention of fungal sepsis in patients with prolonged neutropenia: a randomized, double-blind, placebo-controlled trial of intravenous miconazole. Am J Med 1987:83:1103-10.
25. Verfaillie C, Weisdorf D, Haake R, Hostetter M, Ramsay NKC, McGlave P. Candida infections in bone marrow transplant recipients. Bone Marrow Transplant 1991;8:177-84.
26. Lecciones JA., Lee JW, Navarro EE. et al. Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 1992;14:875-83.
27. Meckstroth KL., Reiss E., Keller JW, Kaufman L. Detection ofantibod-ies and antigenemia in leukemic patients with candidiasis by enzyme-linked immunosorbent assay. J Infect Dis 1981;144:24-32.
28. Segal J, Murray PR, Kobayashi GS, Krogstad DJ. Candida albicans and C. iropicalis fungemia [abstract no 671], In: Program and abstracts of the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington. DC: American Society for Microbiology, 1981.
29. Karabinis A, Hill C. Leclercq B, Tancrede C, Baume D. Andremont A. Risk factors for candidemia in cancer patients: a case-control study. J Clin Microbiol 1988;26:429-32.
30. Tricot G, Joosten E, Boogaerts MA, Vande Pitte J, Cauwenbergh G., Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. Rev Infect Dis 1987;9(suppl 1):S94-9.
31. Komshian SV, Uwaydah AK. Sobel JD, Crane LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989;11:379-90.
32. Richet HM. Andremont A, Tancrede C, Pico JL, Jarvis WR. Risk factors for candidemia in patients with acute lymphocytic leukemia. Revlnfect Dis 1991;13:211-5.
33. Wiley JM, Smith N, Leventhal BG, et al. Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: a multivariate analysis of risk factors. J Clin Oncol 1990;8:280-6.
34. Meunier F. Candidiasis. Eur J Clin Microbiol Infect Dis 1989:8:43847.
35. Powderly WG, Kobayashi GS. Herzig GP, Medofl G. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med 1988;84:826-32.
36. Pfaller M, Cabezudo I, Koontz F, Bale M, Gingrich R. Predictive value of surveillance cultures for systemic infection due to Candida species. Eur J Clin Microbiol 1987;6:628-33.
37. Meunier F, Aoun M, Bitar N. Candidemia in immunocompromised patients. Clin Infect Dis 1992; 14(suppl 1):S120-S125.
38. Martino P, Girmenia C, Venditti M, et al. Candida colonization and systemic infection in neutropenic patients: a retrospective study. Cancer 1989:64:2030-4.
39. Tam JY, Blume KG, Prober CG. Prophylactic fluconazole and Candida krusei infections [letter], N Engl J Med 1992:326:891.
40. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:668-72.
41. Wingard JR. Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991;325:1274-7.
42. Casasnovas R-O, Caillot D, Solary E, et al. Prophylactic fluconazole and Candida krusei infections [letter], N Engl J Med 1992; 326:891-2.
43. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51.
44. Walsh TJ, Rubin M, Hathorn J, et al. Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients: a prospective, randomized study. Arch Intern Med 1991;151:765-70.
45. Wingard JR. Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis g/abrala infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimi-crob Agents Chemother 1993;37:1847-9.
46. Dyess DL, Garrison RN, Fry DE. Candida sepsis: implications of polymicrobial blood-borne infection. Arch Surg 1985;120:345-8.
47. Harvey RL, Myers JP. Nosocomial fungemia in a large community teaching hospital. Arch Intern Med 1987; 147:2117-20.
48. Bryce EA, Roberts FJ, Sekhon AS, Coldman AJ. Yeast in blood cultures: evaluation of factors influencing outcome. Diagn Microbiol Infect Dis 1992;15:233-37.
49. Bross J, Talbot GH, Maislin G, Hurwitz S, Strom BL. Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. Am J Med 1989;87:614-20.
50. Bille J, Stockman L, Roberts GD. Detection of yeasts and filamentous fungi in blood cultures during a 10-year period (1972 to 1981). J Clin Microbiol 1982;16:968-70.
51. Eilard T. Isolation of fungi in blood cultures: a review of fungal infections in the western part of Sweden 1970-1982. Scand J Infect Dis 1987;19:145-56.
52. Richards KE, Pierson CL, Bucciarelli L, Feller I. Monilial sepsis in the surgical patient. Surg Clin North Am 1972;52:1399-406.
53. Joshi N, Hamory BH. Endophthalmitis caused by non-albicans species of Candida. Rev Infect Dis 1991;13:281-7.
54. Stieritz DD, Law EJ, Holder IA. Speciation and amphotericin B sensitivity studies on blood isolates of Candida from burned patients. J Clin Pathol 1973;26:405-8.
55. Schaflner A, Davis CE, Schaffner T, Markert M, Douglas H, Braude AI. In vitro susceptibility of fungi to killing by neutrophil granulocytes discriminates between primary pathogenicity and opportunism. J Clin Invest 1986;78:511-24.
56. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
57. Huppert M, Cazin J. Pathogenesis of Candida albicans infection following antibiotic therapy. II. Further studies of the effect of antibiotics on the in vitro growth of Candida albicans. J Bacteriol 1955;70:435-9.
58. Seligmann E. Virulence enhancement of Candida albicans by antibiotics and cortisone. Proc Soc Exp Biol Med 1953;83:778-81.
59. Lipnik MJ, Kligman AM, Strauss R. Antibiotics and fungous infections. J Invest Dermatol 1952;18:247-60.
60. Torack RM. Fungus infections associated with antibiotic and steroid therapy. Am J Med 1957;22:872-82.
61. Sheldon WH, Bauer H. The role of predisposing factors in experimental fungus infections. Lab Invest 1962; 11:1184-91.
62. Sidransky H, Friedman L. The effect of cortisone and antibiotic agents on experimental pulmonary aspergillosis. Am J Pathol 1959; 35:169-83.
63. Kennedy MJ, Volz PA. Effect of various antibiotics on gastrointestinal colonization and dissemination by Candida albicans. Sabouraudia 1985;23:265-72.
64. Frenkel JK. Role of corticosteroids in predisposing factors in fungal diseases. Lab Invest 1962; 11:1192-208.
65. Louria DB, Fallon N, Browne HG. The influence of cortisone on experimental fungus infections in mice. J Clin Invest 1960;39:1435-49.
66. Mankowski ZT, Littleton BJ. Action of cortisone and ACTH on experimental fungus infections. Antibiot Chemother 1954;4:253-8.
67. Dick JD, Merz WG, Saral R. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother 1980;18:158-63.
68. Merz WG, Sandford GR. Isolation and characterization of a polyene-resistant variant of Candida Iropicalis. J Clin Microbiol 1979;9:677-80.
69. Guinet R, Chanas J, Goullier A, Bonnefoy G, Ambroise-Thomas P. Fatal septicemia due to amphotericin B-resistant Candida lusitan-iae. J Clin Microbiol 1983;18:443-4.
70. Hadfield TL, Smith MB, Winn RE, Rinaldi MG, Guerra C. Mycoses caused by Candida lusilaniae. Rev Infect Dis 1987;9:1006-12.
71. Pappagianis D, Collins MS, Hector R, Remington J. Development of resistance to amphotericin B in Candida lusitaniae infecting a human. Antimicrob Agents Chemother 1979; 16:123-6.
72. Dick JD, Rosengard BR, Merz WG, Stuart RK, Hutchins GM, Saral R. Fatal disseminated candidiasis due to amphotericin-B-resistant Candida guilliermondii. Ann Intern Med 1985;102:67-8.
73. Bignardi GE, Savage MA, Coker R, Davis SG. Fluconazole and Candida krusei infections [letter], J Hosp Infect 1991;18:326-7.
74. Mcllroy MA. Failure of fluconazole to suppress fungemia in a patient with fever, neutropenia and typhlitis [letter], J Infect Dis 1991;163:420-1.
75. Warnock DW, Burke J, Cope NJ, Johnson EM, von Fraunhofer NA, Williams EW. Fluconazole resistance in Candida glabrata [letter]. Lancet 1988;2:1310.
76. Fainstein V, Bodey GP, Elting L, Maksymiuk A, Keating M, McCre-die KB. Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients. Antimicrob Agents Chemother 1987;31:11-5.
77. Burnie JP, Lee W, Williams JD, Matthews RC, Odds FC. Control of an outbreak of systemic Candida albicans. BMJ 1985;291:1092-3.
78. Sharp AM, Odds FC, Evans EGV. Candida strains from neonates in a special care baby unit. Arch Dis Child 1992;67:48-52.
79. Burnie JP, Matthews R, Lee W, et al. Four outbreaks of nosocomial systemic candidiasis. Epidemiol Infect 1987;99:201-11.
80. Matthews R, Burnie J. Assessment of DNA fingerprinting for rapid identification of outbreaks of systemic candidiasis. BMJ 1989; 298:354-7.
81. Podzamczer D, Ventin M, Sauca G, Fernandez-Viladrich P, Martin R, Gudiol F. Contaminated lemons as possible source of infection in heroin abusers with disseminated candidiasis [letter]. Eur J Clin Microbiol 1986;5:477.
82. Fox BC, Mobley HLT, Wade JC. The use of a DNA probe for epidemiological studies of candidiasis in immunocompromised hosts. J Infect Dis 1989;159:488-94.
83. Anaissie E, Kassamali H, Kantarjian H, Elting L, Bodey GP. Changing patterns and outcome of febrile episodes (FE) in patients with acute leukemia [abstract no 967], In: Program and abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy (New York). Washington, DC: American Society for Microbiology, 1987.
84. Wingard JR, Dick JD, Merz WG, Sandford GR, Saral R, Burns WH. Differences in virulence of clinical isolates of Candida iropicalis and Candida albicans in mice. Infect Immun 1982;37:833-6.
85. Wingard JR, Dick JD, Merz WG, Sandford GR, Saral R, Burns WH. Pathogenicity of Candida Iropicalis and Candida albicans after gastrointestinal inoculation in mice. Infect Immun 1980;29:808-13.
86. Walsh TJ, Merz WG. Pathologic features in the human alimentary tract associated with invasiveness of Candida Iropicalis. Am J Clin Pathol 1986;85:498-502.
87. de Repentigny L, Phaneuf M, Mathieu L-G. Gastrointestinal colonization and systemic dissemination by Candida albicans and Candida tropica/is in intact and immunocompromised mice. Infect Immun 1992;60:4907-14.
88. Sandford GR, Merz WG, Wingard JR, Charache P. Saral R. The value of fungal surveillance cultures as predictors of systemic fungal infections. J Infect Dis 1980;142:503-9.
89. Isenberg HD, Tucci V, Cintron F, Singer C, Weinstein GS, Tyras DH. Single-source outbreak of Candida Iropicalis complicating coronary bypass surgery. J Clin Microbiol 1989;27:2426-8.
90. Wickerham LJ. Apparent increase in frequency of infections involving Torulopsis glabrala: procedure for its identification. JAMA 1957;165:47-8.
91. Aisner J, Schimpff SC, Sutherland JC, Young VM, Wiernik PH. Torulopsis glabrata infections in patients with cancer: increasing incidence and relationship to colonization. Am J Med 1976;61:23-8.
92. Merz WG, Karp JE, Schron D, Saral R. Increased incidence of fungemia caused by Candida krusei. J Clin Microbiol 1986;24:581-4.
93. McQuillen DP, Zingman BS, Meunier F, Levitz SM. Invasive infections due to Candida krusei: report of ten cases of fungemia that include three cases of endophthalmitis. Clin Infect Dis 1992; 14:472-8.
94. Abrahamsen TG, Widing E, Glomstein A, Gaustad P. Disseminated fungal disease resistant to fluconazole treatment in a child with leukemia. Scand J Infect Dis 1992;24:391-3.
95. Case CP, MacGowan AP, Brown NM, Reeves DS, Whitehead P, Fel-mingham D. Prophylactic oral fluconazole and Candida fungaemia [letter]. Lancet 1991;337:790.
96. Persons DA, Laughlin M, Tanner D, Perfect J, Gockerman JP, Hath-orn JW. Fluconazole and Candida krusei fungemia [letter], N Engl J Med 1991;325:1315.
97. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia: results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993; 118:495-503.
98. Berger C, Frei R, Gratwohl A, Tichelli A, Hafliger B, Speck B. Epide-mie mit Candida krusei an einer hamatologischen Abteilung. Schweiz Med Wochenschr 1988; 118:37-41.
99. Holzschu DL, Presley HL, Miranda M, Phaff HJ. Identification of Candida lusilaniae as an opportunistic yeast in humans. J Clin Microbiol 1979;10:202-5.
100. Christenson JC, Guruswamy A, Mukwaya G, Rettig PJ. Candida lusilaniae'. an emerging human pathogen. Pediatr Infect Dis J 1987;6:755-7.
101. Merz WG. Candida lusilaniae. frequency of recovery, colonization, infection, and amphotericin B resistance. J Clin Microbiol 1984;20:1194-5.
102. Blinkhorn RJ, Adelstein D, Spagnuolo PJ. Emergence of a new opportunistic pathogen, Candida lusilaniae. J Clin Microbiol 1989; 27:236-40.
103. Sanchez V, Vazquez JA, Barth-Jones D, Dembry L, Sobel JD, Zervos MJ. Epidemiology of nosocomial acquisition of Candida lusilaniae. J Clin Microbiol 1992;30:3005-8.
104. Merz WG, Khazan U, Jabra-Rizk MA., Wu L-C, Osterhout GJ, Lehmann PF. Strain delineation and epidemiology of Candida (Clavi-spora) lusilaniae. J Clin Microbiol 1992;30:449-54.
105. Andriole VT, Hasenclever HF. Factors influencing experimental candidiasis in mice. I. Alloxan diabetes. Yale J Biol Med 1962 63:35:96-1,12.
106. Goldstein E., Grieco MH., Finkel G, Louria DB. Studies on the pathogenesis of experimental Candida parapsilosis and Candida guillier-mondii infections in mice. J Infect Dis 1965:115:293-302.
107. Bistoni F, Vecchiarelli A, Cenci E, Sbaraglia G, Perito S, Cassone A. A comparison of experimental pathogenicity of Candida species in cyclophosphamide-immunodepressed mice. Sabouraudia 1984; 22:409-18.
108. Plouffe JF, Brown DG, Silva J. Eck T, Stricof RL, Fekety FR. Nosocomial outbreak of Candida parapsilosis fungemia related to intravenous infusions. Arch Intern Med 1977;137:1686-9.
109. Weems JJ., Chamberland ME, Ward J., Willy M., Padhye AA, Solomon SL. Candida parapsilosis fungemia associated with parenteral nutrition and contaminated blood pressure transducers. J Clin Microbiol 1987;25:1029-32.
110. Solomon SL., Alexander H, Eley JW, et al. Nosocomial fungemia in neonates associated with intravascular pressure-monitoring devices. Pediatr Infect Dis 1986;5:680-5.
111. Solomon SL., Khabbaz RF, Parker RH, et al. An outbreak of Candida parapsilosis bloodstream infections in patients receiving parenteral nutrition. J Infect Dis 1984;149:98-102.
112. McCray E, Rampell N, Solomon SL, Bond WW, Martone WJ, O'Day D. Outbreak of Candida parapsilosis endophthalmitis after cataract extraction and intraocular lens implantation. J Clin Microbiol 1986;24:625-8.
113. Stern WH, Tamura E, Jacobs RA, et al. Epidemic postsurgical Candida parapsilosis endophthalmitis: clinical findings and management of 15 consecutive cases. Ophthalmology 1985;92:1701-9.
114. Sanchez V, Vazquez JA. Barth-Jones D, Dembry L, Sobel JD, Zervos MJ. Nosocomial acquisition of Candida parapsilosis: an epidemiologic study. Am J Med 1993;94:577-82.
115. Viscoli C, Castagnola E, Fioredda F, Ciravegna B. Barigione G, Terragna A. Fluconazole in the treatment of candidiasis in immunocompromised children. Antimicrob Agents Chemother 1991: 35:365-7.
116. Weems JJ. Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Clin Infect Dis 1992;14:756-66.